Metoclopramide hydrochloride monohydrate
Phase 3Small molecule
Metoclopramide hydrochloride monohydrate is one of 29 small molecule programs targeting Post Operative Nausea and Vomiting. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
33 competitors in Post Operative Nausea and Vomiting
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsApproved
Nicorette
PfizerApproved
Decadron
AAspen Global Incorporated
Approved
Barhemsys
AAcacia Pharma Ltd
Approved
Kytril
CConrado Roberto Hoffmann Filho
Approved
Cardizem
BBausch Health Americas, Inc.
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Neurontin
VViatris Specialty LLC
Approved
Tylenol
KKenvue Brands
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Post Operative Nausea and Vomiting1 trial
Study of Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)for Treatment of Post Operative Nausea and Vomiting
Unknown status·—·Phase 3·NCT01984931·45 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CCM Chungmu Hospital